Suven Life Sciences Ltd (Suven) announces that the grant of one (1) product patent from China (CN105873920) and one (1) product patent from Eurasia (029951) corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2034.
The granted claims of the patents include the class of selective 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
Generally, overnight levitra dosage level of product varies from one person to another. order levitra Carbohydrates and sugar in the food provides necessary sugar in the blood stream. In addition to minerals, also contain magnesium, generic levitra copper, manganese, phosphorous, potassium, iron, sulphur and calcium. If in case you are exercising this pill for the first time, assure you practice it under doctor s support, who very well knows about your cheap cialis deeprootsmag.org body image If you are a man suffering form impotence or Erectile dysfunction in men. ABOUT SUVEN
Suven Life Sciences Ltd (Suven), formerly Suven Pharmaceuticals Pvt Ltd designs, develops, manufactures and supplies bulk actives, drug intermediates and fine chemicals. The company offers active pharmaceutical ingredient products which include aripiprazole, calcium acetate, divalproex sodium, entacapone, fenoprofen calcium, gabapentin, glycopyrrolate, and others. It provides iron sucrose complex for injection, losartan potassium, malathion lotion, nitazoxanide and pamabrom. Suven’s intermediates include diethyl amino cyanoacetamide, dihydroxy nitrobenzaldehyde, triacetoxy deoxyribose and cyclobutanecarbonitrile. The company offers products in forms of solutions, suspensions, emulsions, injectables, lyophilized formulations, ophthalmic and aural preparations, ointments, creams and gels. It operates in the US, Australia, India and New Zealand. Suven is headquartered in Hyderabad, Telangana, India.
The company reported revenues of (Rupee) INR6,252.6 million for the fiscal year ended March 2018 (FY2018), an increase of 14.8% over FY2017. In FY2018, the company’s operating margin was 28.3%, compared to an operating margin of 20% in FY2017. In FY2018, the company recorded a net margin of 19.8%, compared to a net margin of 16% in FY2017.
